Analog Devices stock jumps again — CEO sale filing, chip M&A and Feb. 18 earnings in focus

Analog Devices stock jumps again — CEO sale filing, chip M&A and Feb. 18 earnings in focus

New York, Feb 4, 2026, 15:25 EST — Regular session

  • Analog Devices shares climbed roughly 3.3% in afternoon trading, bouncing back after Tuesday’s drop.
  • Analog chips caught renewed attention as Texas Instruments made a play for Silicon Labs, sparking a fresh round of deal chatter in the sector.
  • Traders are eyeing Analog Devices’ earnings on Feb. 18, spurred by a Form 4 filing revealing CEO Vincent Roche offloaded 10,000 shares.

Shares of Analog Devices Inc rose roughly 3.3% to $321.46 Wednesday afternoon, closing in on the day’s peak after hitting $321.70 earlier.

Analog Devices’ rebound is crucial since the company is seen as a bellwether for the “real economy” segment of semiconductors — the signal and power chips embedded in factory equipment, cars, and medical devices. With earnings just weeks away, this stock move is already shaping expectations before management speaks.

A new M&A move is underway in the analog sector. Texas Instruments has struck a deal to acquire Silicon Laboratories for roughly $7.5 billion. Stifel analysts noted the deal could forge a strong wireless-analog powerhouse. (Reuters)

Texas Instruments pitched the acquisition as a move to boost manufacturing and scale. “Texas Instruments’ … manufacturing … will provide customers dependable supply worldwide,” CEO Haviv Ilan said in a statement unveiling the deal. (PR Newswire)

Inside Analog Devices, Chair and CEO Vincent Roche exercised options before selling 10,000 shares at $306.92 on Feb. 2, according to a regulatory filing. After the sale, he still holds roughly 155,688 shares directly. The filing notes the transaction was conducted under a 10b5-1 plan — a prearranged trading program that lets executives sell shares on a predetermined schedule. (SEC)

The filing follows a volatile session. Analog Devices slipped 1.76% Tuesday, closing at $311.29, but still outperformed several chipmakers amid a broadly weaker U.S. stock market, MarketWatch noted. (MarketWatch)

Investors are marking their calendars. Analog Devices plans to release its first-quarter fiscal 2026 results on Feb. 18, followed by a conference call that same morning with CEO Roche and CFO Richard Puccio. (Analog Devices)

The stock’s relative strength stands out against a choppy backdrop. The iShares Semiconductor ETF dropped roughly 3.3% on the day, making Analog Devices’ gain pop on sector screens.

But here’s the catch: stocks trading near their highs ahead of earnings can take a bigger hit from even slight shifts in outlook. That’s particularly true in semiconductors, where order trends can flip fast, and investors can swing from “recovery” to “pause” within just one quarter.

On Feb. 18, the company will drop its results at 7 a.m. ET, followed by a 10 a.m. ET call. Traders will zero in on any change in demand signals and how assertively the company discusses pricing, lead times, and customer inventory.

Stock Market Today

  • Actinogen Medical and Top ASX Penny Stocks Show Potential Amid Market Headwinds
    February 4, 2026, 3:40 PM EST. The Australian stock market faces pressure from a Reserve Bank rate hike and international tech sell-offs, with ASX 200 futures hinting at a downturn. Yet, ASX penny stocks continue to offer investment opportunities due to their low price points and growth potential. Actinogen Medical (ASX:ACW), a pre-revenue biotechnology firm valued at A$153.2 million, is advancing its Alzheimer's treatment trial and recently secured A$17 million in funding. Despite current unprofitability, Actinogen's innovative approach could spur future revenue growth. Brisbane Broncos Limited (A$181.38 million market cap) operates debt-free in sports management, underlining stability. These stocks exemplify how smaller firms with strong fundamentals may thrive even amid broader market uncertainty.
Chipotle stock rebounds from early drop as CMG traders rethink 2026 outlook
Previous Story

Chipotle stock rebounds from early drop as CMG traders rethink 2026 outlook

Amgen stock price jumps as earnings beat puts MariTide obesity bet back in focus
Next Story

Amgen stock price jumps as earnings beat puts MariTide obesity bet back in focus

Go toTop